VC Investor Launches $125M Life Sciences Fund | GenomeWeb

NEW YORK (GenomeWeb News) – Excel Venture Management, a venture capital firm based in Boston, announced today that it has launched the Excel Medical Fund with $125 million to be invested in early- to late-stage life science platform companies.

Excel said that the new fund will focus its investments on healthcare information technology, services, diagnostics, medical devices, and life sciences platforms with applicability to adjacent industries such as energy, chemicals, defense, and agriculture.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.